Senior-focused primary care orgs get patients to have more visits: While interesting, new findings from the Humana-led study should be taken with a grain of salt. The insurer has skin in the game with its CenterWell Senior Primary Care brand and clinics.
On today's podcast episode, we discuss how physicians are thinking about AI, the specific problems in healthcare that AI is trying to solve, and what it should never be used for in the space. Tune in to the discussion with host Marcus Johnson and analyst Rajiv Leventhal.
Vitamin Shoppe, Marius Pharma sell testosterone replacement therapy: The tie-up should help the supplement retailer acquire customers and the drugmaker get its treatment to more patients.
NYU Langone Health rolls out walk-in primary care: We think it’s a smart patient acquisition play by the health system. Here's why.
Marketers use AI, social media to engage with physicians: Marketers who don’t shift their advertising resources to match doctors’ evolving media consumption habits will fall behind.
The US healthcare system is failing women: Other high-income countries provide better access to affordable care. US brands and marketers can address system-wide failures by better connecting with female patients.
OMNY Health launches GLP-1 data network: We think that structured GLP-1 data could benefit precision medicine efforts.
GenAI tops pharma and health marketers’ list of consumer trends to watch: We’ll be keeping a close eye on whether growing consumer distrust of the tech actually drives adoption down.
New data raises concern about FDA-cleared AI medical devices: Many devices received the FDA stamp without clinical validation. We unpack why FDA approval alone won’t be enough to secure buy-in from end-user clinicians.
Many seniors’ Rx costs will plummet thanks to Inflation Reduction Act: But the projected savings aren’t great for the future of the Medicare program.
Express Scripts removes branded Humira from formularies in 2025: Here’s why the PBM’s move isn’t just a play to lower drug costs for patients but an avenue to drive further profits for parent Cigna.
Healthcare ads show strong vital signs: Industry KPIs illustrate sector’s progress in engaging audiences with high CTRs.
Eli Lilly slashes Zepbound price for cash-pay consumers: Here are three factors behind Lilly’s decision—and what it means for the everchanging weight loss drug market.
Dexcom’s over-the-counter CGM available in the US: Dexcom is in pole position to get its continuous glucose monitors into the hands of millions of adults who don’t use insulin, but getting consumers to buy the pricey devices will be a tall order.
Pfizer rolls out its direct-to-consumer platform: D2C offers Big Pharma a way to contend with the slew of non-traditional players providing seamless access to prescription medications.
Groups for patients with rare diseases have mixed feelings about Big Pharma: We explore how pharma marketers can better support patients who have uncommon medical conditions.
GLP-1s found to reduce the risk of diabetes: Lilly and Novo want the medical community to know that their blockbuster drugs work best when used over a long time.
MA plans score higher than commercial insurance on customer satisfaction: MA insurers that prioritize aspects of the customer experience seniors value the most will maintain their competitive edge.
Employer healthcare costs will surge at the highest rate in 15 years: Pharma spending is the biggest driver. We examine cost-cutting strategies employers might implement.
Sesame rolls out weight loss program offering compounded GLP-1s: Sesame has a limited window of time to extract maximum revenue from the program as competitors race to meet demand for GLP-1s amid drug shortages.